Maxime Dely: What If One Technology Could Transform Patients’ Lives?
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
“Sickle cell disease: What if one technology could transform patients’ lives?
Sickle cell disease is the most common genetic disorder in France, affecting 25,000 to 30,000 people. It remains a complex condition marked by severe pain, microvascular occlusions, strokes, necrosis, jaundice, and episodes of acute hemolytic anemia — all profoundly impacting daily life.
Despite ongoing prevention efforts, the disease continues to progress.
Yet one interventional treatment is truly reshaping patient care: automated red blood cell exchange.
Still underrecognized, this procedure — performed through apheresis systems — brings major benefits supported by numerous studies:
* Drastic reduction in acute crises by removing sickled red cells responsible for vascular occlusion.
* Significantly less iron overload compared with standard transfusion — a crucial long-term advantage.
* Faster procedure, enabling 2 to 3 times more red cell units to be exchanged in the same amount of time.
* More spaced-out sessions, greatly improving comfort and quality of life for patients.
Red blood cell exchange is not just an alternative — it is a major therapeutic advancement for a disease that remains insufficiently visible.
Promoting access to this therapy means offering patients safer, more effective, and more humane care.”
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Jul 11, 2026, 08:37Alejandro González Veliz: Key Takeaways from the 2026 ACC Scientific Statement on Antiplatelet Therapy
-
Jul 11, 2026, 08:35Rono Chonginio: The Power of Visual Storytelling in Healthcare and Non-Profits
-
Jul 11, 2026, 08:35Mavis Agnes Kisakye: Why Patient Identification Begins with an Informed Community
-
Jul 11, 2026, 08:35Leslie Lake: Compression Therapy in Venous Thromboembolism
-
Jul 10, 2026, 22:43Marignima Bennett: Grady Health System Earns the Highest Recognition for Excellence in Stroke Care
-
Jul 10, 2026, 21:31Robert Hamilton: Join NeuraSignal’s Webinar on Real-World Implementation of Robotic TCD in Stroke Care
-
Jul 10, 2026, 20:47New Machine Learning Models Improve Prediction of Thrombosis and Bleeding in Cancer – JTH
-
Jul 10, 2026, 20:39Evangelia Petsalaki: New Systems Biology Approach Identifies Biomarkers in Thrombotic APS
-
Jul 10, 2026, 20:36Sandrine Meunier: Highlights from an Outstanding Meeting on Pediatric Hemostasis